That is CRIS' only revenue stream left, selling stock.
Their drug revenue is gone big pharma competition has beaten them.
CRIS' pipeline is now obsolete or redundant?
They just sold 10 million shares and now they sell another 10 million shares.
Let me guess next month they sell another 10 million shares.
When are the small investors going to learn this company is pure JUNK?
Sorry to say this - been a shareholder since 2004! Bowing out today
CURIS IS DYING A SLOW DEATH !
Only hope is a buyout.
Duckyah000 was right afterall!!!!
Sentiment: Strong Sell
I agree, these past couple of weeks have been very difficult, but now we have to be patient. I haven't sold anything either, just holding for now.
So why are you here on this board..?. I was only sharing info that I didn't see posted anywhere else. May be hard to believe but I am still in profit territory and am definitely expecting more. I must think ducky that you
have lost money on this stock and want everyone to feel your pain and anger/frustration. Best of investing to you!
hopefully everybody has planned a balanced approach at biotech investing. Gains elsewhere should hopefully adjust for the the upset here. I am still holding and have not sold even one stock. It is undeniably under heavy negative pressure now with no reason for active bidding short term. I think extreme patience is required here. I will not try to defeat the market forces here but simply be patient and see what happens.
CURIS is rated a SELL. Due to multiple weaknesses, which some believe should have a
greater impact than any strengths, and could make it very difficult for investors to achieve any positive results
compared to most other stocks anyone covers.
The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow
Jan 21, 2015 - ROTH CAPITAL CUTS PRICE TARGET TO $6 FROM $10; RATING BUY.
Aug 10, 2015 - Roth Capital maintains a Buy rating on Curis and cut the price target to $5.00 (from $6.00).
--- SO, If I would have been stupid and listened to ROTH capital, I would lose all my money.
You should read the reason why ROTH has a Buy on CRIS,
it is for specific drug technology that has already been dominated by big Pharma.
Listen to ROTH capital and lose your money?
I wish these small biotechs cared about share price. The SEC really should revamp some of the unethical ways these companies raise money. I still believe in this company, but it is getting to the point where I might decrease my share count/risk.
Did you listen to the CC?
He denies that Novartis Newly Approved Hh pathway medication will have any impact.
Unless it has an impact. Plus, the CEO was hedged by a very long legal disclaimer at the start of the CC claiming that they are not responsible.....
I think that was the reason the SP continued down, the analysts sounded coached and they could not save face.
I don't trust him at all.
Good point ducky, their cash burn and the CEO's lack of experience will knock the share price back below $2.00
How much will CRIS require for IRAK-4 research financing?
Infancy stage pathway that requires the finances of many big pharmas.
Who is buying the next 10 million shares?